Insiders Oxurion NV

Equities

Market Closed - Euronext Bruxelles Other stock markets 09:54:35 2024-04-26 am EDT			5-day change	1st Jan Change
0.0001 ^EUR	0.00%		0.00%	-88.89%

Apr. 12	Oxurion NV Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 06	Oxurion Raises Additional Funds from Convertible Bonds Issue	MT

Belgium's Oxurion Secures Funding, Evades Bankruptcy; CEO/CFO to Step Down	Dec. 29	MT
Oxurion Announces CEO Changes	Dec. 28	CI
Oxurion Announces Management Changes	Dec. 28	CI
Oxurion NV Announces Board Changes	23-03-14	CI
Oxurion NV Announces Management Changes	21-05-17	CI
Oxurion Nv Announces Executive Changes	21-05-17	CI
Oxurion Nv Appoints Prof Alan Stitt as Chief Scientific Officer	21-01-20	CI
Oxurion Nv Appoints Grace Chang as Chief Medical Officer Effective August 1, 2020	20-08-03	CI
Oxurion NV Announces Board Changes	18-10-29	CI
ThromboGenics NV has Changed its Name to Oxurion NV	18-10-19	CI
ThromboGenics NV will Change its Name to Oxurion NV	18-09-10	CI
ThromboGenics : Strengthens Leadership Team - Susan Schneider, MD appointed Chief Medical Officer and Vinciane Vangeersdaele appointed Chief Commercial Officer	17-11-08	GL
ThromboGenics NV Announces Executive Appoitments	17-11-08	CI
ThromboGenics : Thomas Clay Appointed Chairman of the Board of Directors	17-06-15	PU
ThromboGenics : Long-time Non-executive Director Thomas Clay Appointed Chairman of the Board of Directors	17-06-15	GL
ThromboGenics NV Appoints Thomas Clay as Next Chairman	17-06-15	CI
ThromboGenics Announces Appointment of Emmanuele Attout as Independent Non-Executive Director	15-05-21	CI
ThromboGenics NV Nominates Emmanuele Attout as Independent Non-Executive Director	15-01-22	CI
ThromboGenics NV Appoints Dominique Vanfleteren as New Chief Financial Officer	15-01-07	CI
ThromboGenics NV Announces Executive Changes, Effect from June 30, 2014	14-06-24	CI

No results for this search